SCHEMBL4258058

SCHEMBL4258058

OC1(S)CCCCCCCCCC1

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4261757 1.00 ALDH1A1 (0.38) ALDH1A1
SCHEMBL4257327 1.00 ALDH1A1 (0.38) ALDH1A1
SCHEMBL689599 1.00
SCHEMBL4260879 1.00 ALDH1A1 (0.38) ALDH1A1
SCHEMBL4262599 1.00 ALDH1A1 (0.38) ALDH1A1
SCHEMBL4258822 1.00 ALDH1A1 (0.38) ALDH1A1
SCHEMBL4261588 1.00 ALDH1A1 (0.38) ALDH1A1
SCHEMBL4262604 1.00 ALDH1A1 (0.38) ALDH1A1
SCHEMBL4265274 1.00
SCHEMBL4254128 1.00 ALDH1A1 (0.38) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084625-B2 Crosslinking agent, crosslinking method, method of controlling gene expression, and method of examining gene function WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2011-12-27 US disclosed
US-20090023140-A1 CROSSLINKING AGENT, CROSSLINKING METHOD, METHOD OF CONTROLLING GENE EXPRESSION, AND METHOD OF EXAMINING GENE FUNCTION WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023140-A1 CROSSLINKING AGENT, CROSSLINKING METHOD, METHOD OF CONTROLLING GENE EXPRESSION, AND METHOD OF EXAMINING GENE FUNCTION DCLRE1A, RNGTT, NSUN2 ALDH1A1 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.